Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2005

View Archived Issues

Selank effective in patients with psychogenic anxiety disorders

Diamyd's comments on GAD-gene therapy

Genzyme reviews significant first quarter events

Snapshot of botanicals and natural products in dermatology

New phase II study for PN-2034 in type 2 diabetes

Hormos Medical to become QuatRx subsidiary

U. of Alberta sells BioMS Medical shares

Diatos and Servier sign oncology research agreement for Vectocell

ZOMAXX II study opens enrollment

Agreement on phase III studies of ORG-25969

Swedish approval for phase I study of CAD-106 for Alzheimer's

SPA for phase III GVAX prostate cancer trial

Enrollment begins in phase III study of TMC-114 in HIV

Alliance to pursue proof-of-concept study for Oxygent

Tigecycline reported active against bacterial isolates from centers in Asia

HDP-P-5F2'DU: A novel intravitreally injectable, crystalline prodrug of 5-flourouracil

Hgf naked DNA ameliorates acute colitis in mice

GT-094 shows potential as a chemopreventive agent

Ghrelin analogue RC-1139 exerts gastrokinetic effects in rats

Novel integrin inhibitor delivered via sustained-release implant tested for treating eye diseases

Preclinical and preliminary clinical data indicate interleukin-21 as a promising antitumor therapy

Phase I data on LE-SN-38

deCODE begins phase II trial for asthma

First phase I data on the safety of SB-743921 in patients with solid tumors

Recent patents cover novel treatments for cognitive disorders

Phase IIb trial examines clazosentan for prevention of cerebral vasospasm

New treatments for obesity disclosed

Schering AG announces new treatment option for infertility

CCR2 receptor modulators, SSAO inhibitors revealed in patent literature

Potent antitumor activity demonstrated by inhibitor of KDR tyrosine kinase

New anxioselective agent associated with fewer benzodiazepine-like side effects

Bradykinin B1 receptor antagonism reduces diabetic vascular complications in rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...